Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardelyx, Inc. (Nasdaq: ARDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer with commercial products IBSRELA and XPHOZAH and an active development pipeline, Ardelyx uses SEC reports to describe its financial condition, risk factors, governance and material corporate events.
Current reports on Form 8-K referenced in recent disclosures cover topics such as quarterly financial results, amendments to loan and security agreements, changes to equity incentive plans and bylaws, and transitions in senior management roles. For example, Ardelyx has filed 8-Ks describing appointments and resignations of executive officers, the approval of amendments to its 2014 Equity Incentive Award Plan at the annual meeting of stockholders, and changes to its loan facilities, including new term loans and updated maturity dates.
On this page, users can also locate periodic reports such as Forms 10-K and 10-Q, which contain detailed financial statements, management’s discussion and analysis, descriptions of the company’s products IBSRELA and XPHOZAH, discussions of its NHE3 inhibitor pipeline and summaries of key risks related to drug development and commercialization. These filings provide context for revenue from tenapanor-based products, licensing arrangements with partners such as Kyowa Kirin, Fosun Pharma and Knight Therapeutics, and capital structure information.
Stock Titan enhances access to Ardelyx filings with AI-powered summaries that highlight important sections in lengthy documents, such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Users can also review filings related to executive compensation, equity plans and governance changes, as disclosed in proxy materials and associated 8-Ks. Real-time updates from the EDGAR system help ensure that new Ardelyx filings, including future 8-Ks reporting material events, are reflected promptly for investors and researchers.
Ardelyx, Inc. executive Brady James Parker, the Chief Human Resources Officer, reported selling a total of 2,543 shares of common stock on February 20, 2026 in open-market transactions at prices of $5.865 and $5.7138 per share.
According to the footnote, these sales were an automatic sell-to-cover triggered upon the vesting of restricted stock units and were executed solely to cover applicable withholding taxes. After the transactions, Parker directly owned 262,912 Ardelyx shares.
Ardelyx, Inc. officer Mike Kelliher reported automatic sales of company common stock tied to vested restricted stock units. On February 20, 2026, he sold a total of 9,595 shares in open-market transactions at prices around $5.71–$5.87 per share.
According to the footnote, these were “automatic sell-to-cover” transactions required under the original RSU grant terms and were executed solely to cover withholding taxes, rather than discretionary sales. After these transactions, Kelliher directly holds 364,666 shares of Ardelyx common stock.
ARDELYX, INC. President & CEO Michael Raab reported open-market sales of a total of 45,982 shares of common stock on February 20, 2026, at prices around $5.70 to $5.87 per share. According to the filing, these sales were executed pursuant to an automatic sell-to-cover feature tied to restricted stock unit vesting and were made solely to cover applicable withholding taxes.
After these transactions, Raab directly holds 1,856,988 shares as trustee of the Michael G. Raab Living Trust dated July 25, 2012, and also has indirect ownership of 24,364 and 1,000 shares through trusts established for his children.
Ardelyx, Inc. Chief Commercial Officer Eric Duane Foster reported open-market sales of a total of 10,439 shares of common stock on February 20, 2026, at prices between $5.7003 and $5.865 per share. According to the footnote, these trades were executed automatically to sell shares upon restricted stock unit vesting solely to cover withholding taxes. After these transactions, he directly owned 425,970 Ardelyx common shares.
ARDX filed an amended Form 144/A disclosing a proposed sale of common stock, listing 10,388 shares tied to restricted stock unit vesting on 02/19/2026. The filing also reports a prior sale by Joseph James Reilly of 11,086 shares on 11/21/2025.
Laura A. Williams reports proposed sale of 24,041 shares of Common Stock. The filing lists 24,041 shares associated with the vesting of restricted stock units on 02/19/2026, described as arising from services rendered.
The notice also records sales during the prior three months: 6,426 shares on 11/21/2025 for $35,580.12 and 50,000 shares on 01/08/2026 for $348,900.00. The broker listed is Morgan Stanley Smith Barney LLC.
ARDX submitted a Form 144 reporting proposed sales of Common Stock. The filing lists 11,800 shares, notes 24,986 shares tied to the vesting of restricted stock units on 02/19/2026, and discloses a prior sale of 5,560 shares on 11/21/2025.
ARDX affiliate filed a notice to sell common stock. The filing identifies the vesting of 10,388 restricted stock units on 02/19/2026 as the source of securities to be sold. The filing also records a prior sale of 11,086 shares on 11/21/2025 for $61,382.07.
Eric Duane Foster submitted a notice of proposed sale of 28,415 shares of Common Stock following vesting of restricted stock units on 02/19/2026. The filing also discloses a prior sale of 5,814 shares on 11/21/2025 and lists Morgan Stanley Smith Barney LLC as the broker.
ARDX insider filing notifies a proposed resale of 51,100 shares of common stock through Morgan Stanley Smith Barney LLC, dated 02/20/2026. The filing also lists 108,840 shares issued on 02/19/2026 upon vesting of restricted stock units for services rendered. The filing records a prior sale by Michael Raab of 46,887 shares on 11/21/2025 for $259,608.63.